PTC Therapeutics (NASDAQ:PTCT) Rating Lowered to “Hold” at Wall Street Zen

Posted by Brian Himes on Nov 2nd, 2026

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other equities analysts have also recently weighed in on PTCT. Royal Bank Of Canada lifted their price objective on PTC Therapeutics from $75.00 to $77.00 and gave the company a “sector perform” rating in a report on Friday. Truist Financial began coverage on shares of PTC Therapeutics in a report on Friday, October 16th. They issued a “hold” rating and a $62.00 price target for the company. Leerink Partners assumed coverage on shares of PTC Therapeutics in a report on Monday, September 14th. They set an “outperform” rating and a $98.00 price objective on the stock. Weiss Ratings raised shares of PTC Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. Finally, Barclays upped their target price on shares of PTC Therapeutics from $120.00 to $122.00 and gave the stock an “overweight” rating in a research note on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $95.64.

Check Out Our Latest Stock Report on PTC Therapeutics

PTC Therapeutics Price Performance

PTCT stock opened at $59.97 on Friday. The company has a market cap of $5.01 billion, a P/E ratio of -42.84, a price-to-earnings-growth ratio of 1.81 and a beta of 0.52. The business’s fifty day moving average is $65.36 and its 200-day moving average is $70.78. PTC Therapeutics has a twelve month low of $58.80 and a twelve month high of $90.87.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by ($0.76). The firm had revenue of $357.81 million for the quarter, compared to the consensus estimate of $306.43 million. The firm’s revenue for the quarter was up 69.6% compared to the same quarter last year. During the same period last year, the business earned $0.20 earnings per share. Research analysts anticipate that PTC Therapeutics will post 1.19 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other PTC Therapeutics news, VP Mark Boulding sold 435 shares of PTC Therapeutics stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $64.16, for a total value of $27,909.60. Following the completion of the sale, the vice president directly owned 105,272 shares of the company’s stock, valued at approximately $6,754,251.52. The trade was a 0.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Glenn Steele, Jr. sold 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $65.16, for a total value of $781,920.00. Following the transaction, the director directly owned 22,500 shares in the company, valued at $1,466,100. The trade was a 34.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 77,370 shares of company stock worth $5,322,261. 5.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On PTC Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in PTC Therapeutics in the second quarter worth $1,139,089,000. Jupiter Topco LLC bought a new position in shares of PTC Therapeutics during the second quarter valued at approximately $590,182,000. Janus Henderson Group PLC lifted its stake in shares of PTC Therapeutics by 48.3% in the 1st quarter. Janus Henderson Group PLC now owns 7,193,433 shares of the biopharmaceutical company’s stock valued at $489,997,000 after purchasing an additional 2,342,101 shares during the period. Wellington Management Group LLP increased its position in PTC Therapeutics by 4.7% during the 2nd quarter. Wellington Management Group LLP now owns 4,128,273 shares of the biopharmaceutical company’s stock valued at $336,743,000 after buying an additional 185,663 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in PTC Therapeutics by 31.8% in the 1st quarter. Bank of America Corp DE now owns 1,886,841 shares of the biopharmaceutical company’s stock worth $128,550,000 after acquiring an additional 455,284 shares during the last quarter.

Key PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

Positive Sentiment: Raised 2026 outlook and strong revenue growth: PTC reported third-quarter revenue of approximately $358 million, up 69.6% year over year, including $276 million in product revenue. Management increased full-year 2026 revenue guidance to $1.29 billion-$1.32 billion and product revenue guidance to $960 million-$990 million. Sephience revenue reached $182 million, supported by U.S. growth and international expansion. PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Positive Sentiment: Analysts raised price targets: TD Cowen lifted its target from $90 to $95 and maintained a “buy” rating. Wells Fargo raised its target from $109 to $112 and kept an “overweight” rating, signaling substantial potential upside based on the current valuation. TD Cowen recommendations Wells Fargo price target update
Positive Sentiment: Pipeline expansion: PTC acquired ST-920, a Fabry disease gene therapy, and expects to complete its biologics license application submission in the fourth quarter, adding a potential future growth catalyst. PTC corporate update
Neutral Sentiment: Royal Bank of Canada raised its price target from $75 to $77 but retained a “sector perform” rating, indicating improved valuation expectations without a bullish change in its recommendation. RBC recommendations
Negative Sentiment: Quarterly loss weighed on sentiment: PTC reported a GAAP loss of $0.62 per share, versus analysts’ expected profit of $0.14. Although revenue exceeded estimates, the earnings miss and swing from a year-earlier profit create near-term concern. Some reports cite adjusted earnings of $0.61 per share, highlighting a difference in reporting methodology. PTC Therapeutics swings to Q3 loss

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.